Bicycle Therapeutics (BCYC) Common Equity (2018 - 2026)

Bicycle Therapeutics has reported Common Equity for 9 years, with the latest figure at $554.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 25.13% year-over-year to $554.3 million; the trailing twelve-month figure through Mar 2026 stood at $554.3 million (down 25.13% YoY), and the FY2025 full-year result was $610.0 million, down 23.09% from the prior year.
• Common Equity for Q1 2026 stood at $554.3 million, down from $610.0 million in the prior quarter.
• The five-year high for Common Equity was $873.8 million in Q2 2024, with the low at $220.1 million in Q2 2023.
• Historically, Common Equity has averaged $499.9 million across 5 years, with a median of $416.0 million in 2023.
• Annual changes were most pronounced in 2023 — Common Equity slipped 29.32% — and 2024, when it surged 297.01%.
• Bicycle Therapeutics' Common Equity stood at $270.8 million in 2022, then surged by 36.98% to $370.9 million in 2023, then surged by 113.8% to $793.1 million in 2024, then declined by 23.09% to $610.0 million in 2025, then decreased by 9.12% to $554.3 million in 2026.
• The last three Common Equity figures came in at $554.3 million (Q1 2026), $610.0 million (Q4 2025), and $618.5 million (Q3 2025), per Business Quant data.